|
|
|
Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study
|
|
Yu Gu, Junhua Zhang, Zhirui Zhou, Di Liu, Hongcheng Zhu, Junmiao Wen, Xinyan Xu, Tianxiang Chen, Min Fan
|
|
| |
| Table 1 Characteristics of patients with extrathoracic metastatic AD and NAD by age groups. |
|
| AD | NAD |
|---|
| <=59 yrs | 60-79 yrs | >=80 yrs | Total | P value | <=59 yrs | 60-79 yrs | 80yrs | Total | p-value |
|---|
| (n=6757, 31.1%) | (n=12500, 57.5%) | (n=2465, 11.3%) | (n = 21722) | (n =1195, 14.2%) | (n = 5296, 62.9%) | (n =1929, 22.9%) | (n = 8420) | |
|---|
| Race | | | Black | 1168(17.3%) | 1471(11.8%) | 154(6.2%) | 2793(12.9%) | <0.001 | 296(15.3%) | 734(13.9%) | 98(08.2%) | 1128(13.4%) | <0.001 | | White | 4821(71.3%) | 9771(78.2%) | 2039(82.7%) | 16631(76.6%) | 1508(78.2%) | 4243(80.1%) | 1014(84.9%) | 6765(80.3%) | | Other# | 746(11.0%) | 1227(9.8%) | 268(10.9%) | 2241(10.3%) | 120(6.2%) | 316(6.0%) | 80(6.7%) | 516(6.1%) | | Unknown | 22(0.3%) | 31(0.2%) | 4(0.2%) | 57(0.3%) | 5(0.3%) | 3(0.1%) | 3(0.3%) | 11(0.1%) | | Gender | | | Male | 3584(53.0%) | 6750(54.0%) | 1165(47.3%) | 11499(52.9%) | <0.001 | 1292(67.0%) | 3401(64.2%) | 711(59.5%) | 5404(64.2%) | <0.001 | | Female | 3173(47.0%) | 5750(46.0%) | 1300(52.7%) | 10223(47.1%) | 637(33.0%) | 1895(35.8%) | 484(40.5%) | 3016(35.8%) | | Histologic grade | | | Well | 120(1.8%) | 267(2.1%) | 73(3.0%) | 460(2.1%) | <0.001 | 23(1.2%) | 71(1.3%) | 19(1.6%) | 113(1.3%) | 0.003 | | Moderately | 749(11.1%) | 1430(11.4%) | 266(10.8%) | 2445(11.3%) | 221(11.5%) | 729(13.8%) | 180(15.1%) | 1130(13.4%) | | Poorly | 1673(24.8%) | 3065(24.5%) | 518(21.0%) | 5256(24.2%) | 594(30.8%) | 1700(32.1%) | 349(29.2%) | 2643(31.4%) | | Undifferentiated | 47(0.7%) | 59(0.5%) | 11(0.4%) | 117(0.5%) | 61(3.2%) | 150(2.8%) | 19(1.6%) | 230(2.7%) | | Unknown | 4168(61.7%) | 7679(61.4%) | 1597(64.8%) | 13444(61.9%) | 1030(53.4%) | 2646(50.0%) | 628(52.6%) | 4304(51.1%) | | T stage | | | T0 | 69(1.0%) | 129(1.0%) | 21(0.9%) | 219(1.0%) | 0.014 | 23(1.2%) | 37(0.7%) | 7(0.6%) | 67(0.8%) | 0.09 | | T1 | 779(11.5%) | 1476(11.8%) | 263(10.7%) | 2518(11.6%) | 138(7.2%) | 357(6.7%) | 73(6.1%) | 568(6.7%) | | T2 | 1518(22.5%) | 3006(24.0%) | 598(24.3%) | 5122(23.6%) | 459(23.8%) | 1331(25.1%) | 298(24.9%) | 2088(24.8%) | | T3 | 1524(22.6%) | 2648(21.2%) | 523(21.2%) | 4695(21.6%) | 464(24.1%) | 1351(25.5%) | 312(26.1%) | 2127(25.3%) | | T4 | 1959(29.0%) | 3492(27.9%) | 670(27.2%) | 6121(28.2%) | 620(32.1%) | 1620(30.6%) | 342(28.6%) | 2582(30.7%) | | Tx | 908(13.4%) | 1749(14.0%) | 390(15.8%) | 3047(14.0%) | 225(11.7%) | 600(11.3%) | 163(13.6%) | 988(11.7%) | | N stage | | | N0 | 1229(18.2%) | 2612(20.9%) | 654(26.5%) | 4495(20.7%) | <0.001 | 305(15.8%) | 1090(20.6%) | 337(28.2%) | 1732(20.6%) | <0.001 | | N1 | 474(7.0%) | 1004(8.0%) | 169(6.9%) | 1647(7.6%) | 136(7.1%) | 464(8.8%) | 103(8.6%) | 703(8.3%) | | N2 | 2976(44.0%) | 5488(43.9%) | 1026(41.6%) | 9490(43.7%) | 894(46.3%) | 2456(46.4%) | 503(42.1%) | 3853(45.8%) | | N3 | 1712(25.3%) | 2538(20.3%) | 372(15.1%) | 4622(21.3%) | 495(25.7%) | 967(18.3%) | 157(13.1%) | 1619(19.2%) | | Nx | 366(5.4%) | 858(6.9%) | 244(9.9%) | 1468(6.8%) | 99(5.1%) | 319(6.0%) | 95(7.9%) | 513(6.1%) | | Treatment | | | Radiotherapy | 3933(58.2%) | 6118(48.9%) | 926(37.6%) | 10977(50.5%) | <0.001 | 1109(57.5%) | 2497(47.1%) | 433(36.2%) | 4039(48.0%) | <0.001 | | Surgery and diotherapy | 151(2.2%) | 144(1.2%) | 6(0.2%) | 301(1.4%) | 45(2.3%) | 83(1.6%) | 6(0.5%) | 134(1.6%) | | No therapy | 2477(36.7%) | 5916(47.3%) | 1483(60.2%) | 9876(45.5%) | 699(36.2%) | 2559(48.3%) | 724(60.6%) | 3982(47.3%) | | Surgery | 91(1.3%) | 152(1.2%) | 17(0.7%) | 260(1.2%) | 36(1.9%) | 65(1.2%) | 12(1.0%) | 113(1.3%) | | Unknown | 105(1.6%) | 170(1.4%) | 33(1.3%) | 308(1.4%) | 40(2.1%) | 92(1.7%) | 20(1.7%) | 152(1.8%) |
|
|
|